S'abonner

Associations of elevated Interleukin-6 and C-Reactive protein levels with mortality in the elderly - 08/09/11

Doi : 10.1016/S0002-9343(99)00066-2 
Tamara B Harris, MD, MS a, , Luigi Ferrucci, MD, PhD b, Russell P Tracy, PhD c, M.Chiara Corti, MD, PhD d, Sholom Wacholder, PhD e, Walter H Ettinger, MD, MBA f, Harley Heimovitz, MS g, Harvey J Cohen, MD h, Robert Wallace, MD, MSc i
a Epidemiology, Demography and Biometry Program (TBH), National Institute on Aging, Bethesda, Maryland, USA 
b National Research Institute (INRCA) (LF), Florence, Italy 
c University of Vermont (RPT), Burlington, Vermont, USA 
d University of Padova (MCC), Padova, Italy 
e National Cancer Institute (SW), Bethesda, Maryland, USA 
f Bowman Gray School of Medicine (WHE), Winston-Salem, North Carolina, USA 
g Sytel (HH), Bethesda, Maryland, USA 
h Duke University School of Medicine (HJC), Durham, North Carolina, USA 
i University of Iowa College of Medicine (RW), Iowa City, Iowa, USA 

*Requests for reprints should be addressed to Tamara B. Harris, MD, MS, Epidemiology, Demography and Biometry Program, National Institute on Aging, Gateway Building, Room 3C-309, 7201 Wisconsin Avenue, Bethesda, Maryland 20892-9205

Abstract

PURPOSE: To investigate whether interleukin-6 and C-reactive protein levels predict all-cause and cause-specific mortality in a population-based sample of nondisabled older people.

SUBJECTS AND METHODS: A sample of 1,293 healthy, nondisabled participants in the Iowa 65+ Rural Health Study was followed prospectively for a mean of 4.6 years. Plasma interleukin-6 and C-reactive protein levels were measured in specimens obtained from 1987 to 1989.

RESULTS: Higher interleukin-6 levels were associated with a twofold greater risk of death [relative risk (RR) for the highest quartile (≥3.19 pg/mL) compared with the lowest quartile of 1.9 [95% confidence interval, CI, 1.2 to 3.1]). Higher C-reactive protein levels (≥2.78 mg/L) were also associated with increased risk (RR = 1.6; CI, 1.0 to 2.6). Subjects with elevation of both interleukin-6 and C-reactive protein levels were 2.6 times more likely (CI, 1.6 to 4.3) to die during follow-up than those with low levels of both measurements. Similar results were found for cardiovascular and noncardiovascular causes of death, as well as when subjects were stratified by sex, smoking status, and prior cardiovascular disease, and for both early (<2.3 years) and later follow-up. Results were independent of age, sex, body mass index, and history of smoking, diabetes, and cardiovascular disease, as well as known indicators of inflammation including fibrinogen and albumin levels and white blood cell count.

CONCLUSIONS: Higher circulating levels of interleukin-6 and C-reactive protein were associated with mortality in this population-based sample of healthy older persons. These measures may be useful for identification of high-risk subgroups for anti-inflammatory interventions.

Le texte complet de cet article est disponible en PDF.

Plan


 Supported in part by National Institute on Aging Contract AG-0-2106. This paper was finalized when Drs. Ferrucci and Corti were Visiting Scientists in the Epidemiology, Demography and Biometry Program at the National Institute on Aging.


© 1999  Excerpta Medica Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 106 - N° 5

P. 506-512 - mai 1999 Retour au numéro
Article précédent Article précédent
  • Successful implementation of guidelines for encouraging the use of beta blockers in patients after acute myocardial infarction
  • François P Sarasin, Maria-Luisa Maschiangelo, Marie-Denise Schaller, Céliane Héliot, Sandrine Mischler, Jean-Michel Gaspoz
| Article suivant Article suivant
  • A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone
  • Paul D Miller, Jacques P Brown, Ethel S Siris, Mohammad S Hoseyni, Douglas W Axelrod, Pirow J Bekker, for the Paget’s Risedronate/Etidronate Study Group

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.